PBLA   $1.04  -10.57% Market Open

Panbela Therapeutics Inc
Last Events:

2023-08-05 Trend pattern changed from нисходящий треугольник to симметричный треугольник.

2023-08-05 Signal in Stochastic changed from bearish to bearish recovery. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: main and signal line crossing.

2023-08-04 Signal in Stochastic changed from bullish to bearish. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: down-crossing the middle level.

2023-08-04 Signal in MACD changed from bearish weakening to bearish recovery. Oscillator MACD is in the negative territory it's higher than the signal line and falls. These factors mean that negative mood prevails, but this trend does not have a significant strength. Last signal: main and signal line crossing.

2023-08-04 Signal in EMA100 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-03 Trend pattern changed from симметричный треугольник to нисходящий треугольник.

2023-08-03 Signal in Stochastic changed from bullish reversal to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.

2023-08-03 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.


Current temperature: 1.56
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 2
Target Price Mean 410.00
Mean unverified/preliminary 410.00 / 410.00
Target Price Low / High 320.00 / 500.00
Median / STD DEV 410.00 / 127.28
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total ActivelyBuy ActivelyBuy ActivelyBuy
rsi ActivelyBuy ActivelyBuy ActivelyBuy
macd None None None
stoch None None None
ma20 ActivelyBuy ActivelyBuy ActivelyBuy
ma50 None None None
ma100 Sell None None
Candlestick PatternNov. 13, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US69833W3051
ceo Dr. Jennifer K. Simpson CRNP, M.S.N., Ph.D.
Website https://www.panbela.com
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase. It has a research agreement with the Johns Hopkins University School of Medicine for the development of Panbela's investigative agent ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.